# The CONFUCIUS Oral Protein Supplementation Trial

> **NCT05405764** · NA · TERMINATED · sponsor: **ARH van Zanten** · enrollment: 15 (actual)

## Conditions studied

- Intensive Care Unit Acquired Weakness
- Critical Illness

## Interventions

- **DIETARY_SUPPLEMENT:** Porcine protein supplement
- **DIETARY_SUPPLEMENT:** Control product maltodextrin supplement

## Key facts

- **NCT ID:** NCT05405764
- **Lead sponsor:** ARH van Zanten
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-19
- **Primary completion:** 2024-09-24
- **Final completion:** 2024-09-24
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Slow inclusion rate
- **Last updated:** 2024-09-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05405764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05405764, "The CONFUCIUS Oral Protein Supplementation Trial". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05405764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*